UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin resistance

Journal of Cancer

Volumn 4, Issue 8, 2013, Pages 662-670

  Jin, Chengmeng ^a,b,d   Yu, Wei ^c,d   Lou, Xiaoyan ^a,d   Zhou, Fan ^a,d   Han, Xu ^c,d   Zhao, Na ^a,d   Lin, Biaoyang ^a,b,d,e,f  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^d ZHEJIANG UNIVERSITY   (China)

^e SWEDISH MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Tumor suppressor; Ubiquitin carboxyl terminal hydrolase 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; PROTEIN BAX; PROTEIN P53; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 84885443904     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6641     Document Type: Article

References (38)

1. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005; 5: 355-66.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012; 62: 10-29.
3. Sekiguchi S, Yoshikawa Y, Tanaka S, et al. Immunohistochemical analysis of protein gene product 9.5, a ubiquitin carboxyl-terminal hydrolase, during placental and embryonic development in the mouse. Exp Anim Tokyo. 2003; 52: 365-9.
4. Wilkinson KD, Lee K, Deshpande S, Duerksenhughes P, Boss JM, Pohl J. The Neuron-Specific Protein Pgp-9.5 Is a Ubiquitin Carboxyl-Terminal Hydrolase. Science. 1989; 246: 670-3.
5. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007; 51: 105-11.
6. Hussain S, Foreman O, Perkins SL, et al. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia. 2010; 24: 1641-55.
7. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Lee KJ. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2008; 28: 117-27.
8. Zhong J, Zhao M, Ma Y, et al. UCHL1 acts as a colorectal cancer oncogene via activation of the beta-catenin/TCF pathway through its deubiquitinating activity. Int J Mol Med. 2012; 30: 430-6.
9. Li L, Tao Q, Jin H, et al. The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma. Clinical Cancer Research. 2010; 16: 2949-58.
10. Bonazzi VF, Nancarrow DJ, Stark MS, et al. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One. 2011; 6: e26121.
11. Yu J, Tao Q, Cheung KF, et al. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology. 2008; 48: 508-18.
12. Mandelker DL, Yamashita K, Tokumaru Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res. 2005; 65: 4963-8.
13. Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. Journal of Translational Medicine. 2009; 7: 90.
14. Yamashita K, Park HL, Kim MS, et al. PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res. 2006; 66: 3921-7.
15. Ummanni R, Jost E, Braig M, et al. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Mol Cancer. 2011; 10:129.
16. Einhorn LH. Testicular cancer: An oncological success story. Clinical Cancer Research. 1997; 3: 2630-2.
17. Gong F, Peng X, Zeng Z, Yu M, Zhao Y, Tong A. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol Cell Biochem. 2011; 348: 141-7.
18. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18: 1427-31.
19. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003; 4: R28.
20. Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006; 119: 1338-44.
21. Petru E, Sevin BU, Perras J, et al. Comparative Chemosensitivity Profiles in 4 Human Ovarian-Carcinoma Cell-Lines Measuring Atp Bioluminescence. Gynecologic Oncology. 1990; 38: 155-60.
22. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research. 2002; 62: 6559-65.
23. Wang Y, Niu XL, Qu Y, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Letters. 2010; 295: 110-23.
24. Yu W, Jin CM, Lou XY, et al. Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell. Plos One. 2011; 6.
25. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993; 74: 609-19.
26. Xiang T, Li L, Yin X, et al. The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast Cancer. PLoS One. 2012; 7: e29783.
27. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6: 99-104.
28. Liu XP, et al. Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells. International Journal of Oncology. 2008;33:1037-1045.
29. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther. 2005; 4: 1605-16.
30. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986; 46: 1972-9.
31. Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, Calvert AH. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer. 1989; 60: 767-9.
32. Boven E, van der Vijgh WJ, Nauta MM, Schluper HM, Pinedo HM. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 1985; 45: 86-90.
33. Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of theUCHL1 gene in human colorectal and ovarian cancers. International Journal of Cancer. 2006; 119: 1338-44.
34. Kawase T, Ichikawa H, Ohta T, et al. p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis. Oncogene. 2008; 27: 3797-810.
35. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993; 4: 327-32.
36. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 1996; 56: 1834-41.
37. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001; 61: 1862-8.
38. Ma JJ, Chen BL, Xin XY. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2009; 146: 222-6.